Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 296

Similar articles for PubMed (Select 23721300)

1.

Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.

Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P.

Acta Oncol. 2014 Jan;53(1):113-8. doi: 10.3109/0284186X.2013.794957. Epub 2013 May 30.

PMID:
23721300
3.

Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.

Vrdoljak E, Gore M, Leyman S, Szczylik C, Kharkevich G, Schöffski P, Torday L, Mardiak J, Zhang K, Sajben P, Sella A.

Future Oncol. 2015 Jun 29:1-10. [Epub ahead of print]

PMID:
26118456
4.

TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

Verzoni E, Grassi P, Montone R, Galli G, Necchi A, Procopio G.

Tumori. 2015 Jun 20;0(0):0. doi: 10.5301/tj.5000335. [Epub ahead of print]

PMID:
26108242
5.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R.

Br J Cancer. 2015 Jun 30;113(1):12-9. doi: 10.1038/bjc.2015.196. Epub 2015 Jun 18.

PMID:
26086878
6.

Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma.

Behzadigohar R, Rosenthal MA, Tran B.

Can J Urol. 2015 Jun;22(3):7824-6.

PMID:
26068633
7.
8.

Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.

Kucharz J, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Herman RM, Krzemieniecki K.

Tumori. 2015 Jun 5;0(0):0. doi: 10.5301/tj.5000342. [Epub ahead of print]

PMID:
26045121
9.

Pazopanib-induced alopecia, an underestimated toxicity?

Biondo A, Alexander H, Khabra K, Pickering L, Gore M, Larkin J.

Front Oncol. 2015 May 11;5:112. doi: 10.3389/fonc.2015.00112. eCollection 2015.

10.
11.

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.

Takayoshi K, Sagara K, Uchino K, Kusaba H, Sakamoto N, Iguchi A, Baba E.

BMC Cancer. 2015 May 22;15:426. doi: 10.1186/s12885-015-1443-2.

12.

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.

Bally O, Tassy L, Richioud B, Decouvelaere AV, Blay JY, Derbel O.

Clin Sarcoma Res. 2015 Apr 23;5:12. doi: 10.1186/s13569-014-0018-3. eCollection 2015.

13.

Pazopanib and pancreatic toxicity: a case report.

Russano M, Vincenzi B, Venditti O, D'Onofrio L, Ratta R, Guida FM, Tonini G, Santini D.

BMC Res Notes. 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4.

14.
15.

Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.

Abdallah AO, Vallurupalli S, Kunthur A.

J Oncol Pharm Pract. 2015 May 7. pii: 1078155215585189. [Epub ahead of print] No abstract available.

PMID:
25956420
16.

Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Bozkurt O, Karaca H, Hacıbekiroglu I, Kaplan MA, Duzkopru Y, Uysal M, Berk V, Inanc M, Duran AO, Ozaslan E, Ucar M, Ozkan M.

J Chemother. 2015 May 6:1973947815Y0000000039. [Epub ahead of print]

PMID:
25948423
17.

Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].

Trump D.

Urol Oncol. 2015 Apr 30. pii: S1078-1439(15)00123-4. doi: 10.1016/j.urolonc.2015.03.015. [Epub ahead of print]

PMID:
25937427
18.

CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma.

Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, Rini BI, Guchelaar HJ.

Eur Urol. 2015 Apr 27. pii: S0302-2838(15)00320-6. doi: 10.1016/j.eururo.2015.04.018. [Epub ahead of print]

PMID:
25930089
19.

Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.

Bergmann L, Kube U, Doehn C, Steiner T, Goebell PJ, Kindler M, Herrmann E, Janssen J, Weikert S, Scheffler MT, Schmitz J, Albrecht M, Staehler M.

BMC Cancer. 2015 Apr 18;15:303. doi: 10.1186/s12885-015-1309-7.

20.

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.

Spraggs CF, Parham LR, Song K, Briley LP, Johnson T, Russo M, Tada H, du Bois A, Xu CF.

Ann Oncol. 2015 Jul;26(7):1515-7. doi: 10.1093/annonc/mdv211. Epub 2015 Apr 28. No abstract available.

PMID:
25922065
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk